Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Human/Mouse AP3B2 (aa 260-274), Synthetic Peptide, Invitrogen™

Synthetic Peptide

Manufacturer:  Invitrogen PEP294

Catalog No. 01-670-214

This item has been discontinued by the manufacturer and is no longer available. Please call customer service for assistance: 1-800-766-7000.



Human and Mouse Beta-NAP (residues 260-274) Synthetic Peptide, PEP-294, from Invitrogen.

PEP-294 is a mixture of two, 15 amino acid synthetic peptides whose sequences correspond to residues 260-274 of human and mouse beta-NAP. The sequence of these peptides is (amino to carboxyl terminus): L (260) L E E N A/P E K A F Y G S E E (274).This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product, beta-NAP, catalog # PA1-1067. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~70-fold) for competitive inhibition of antibody-protein binding reactions.


Human, Mouse
11775, 8120
Human, Mouse
peptide with no preservative
L(260) L E E N A/P E K A F Y G S E E(274)
-20° C, Avoid Freeze/Thaw Cycles
Adapter-related protein complex 3 beta-2 subunit; Beta3B-adaptin; Adaptor protein complex AP-3 beta-2 subunit; AP-3 complex beta-2 subunit; Clathrin a
Synthetic Peptide
No preservative
Human/Mouse AP3B2 (aa 260-274)
Q13367, Q9JME5
Product Certifications
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit